The nuclear medicine department of the Institut Jules Bordet offers patients diagnostic tests of the functional or molecular type, as well as treatments with targeted molecular radiotherapy.
The diagnostic tests differ from those carried out in the Radiology Department in that they involve the intravenous administration of substances labelled with radioactive isotopes, which specifically make it possible to identify the functionality or characteristic of an organ or of the cancer.
Therapeutic applications in nuclear medicine (often called “molecular radiotherapy”) use the same type of substance (tracer) specifically targeting the cancer tissue, but this substance is labelled with radioactive isotopes which emit therapeutic particles of the beta or alpha type enabling the destruction of the diseased cells.
The Department of Nuclear Medicine has 4 units:
1) Conventional nuclear medicine
This unit offers all the usual non-PET examinations, using either gamma-emitting radionuclides, or substances labelled using gamma-emitting radioelements. In 2016, the Department of Nuclear Medicine carried out 3500 “conventional” nuclear medicine examinations.
The Department is equipped with a classical (2-headed) gamma camera and a latest generation hybrid SPECT-CT camera. The latter combines a gamma ray detector (2 heads) with a helicoidal CT scanner. This technology makes it possible to obtain a complete evaluation of the functional and anatomical/morphological characteristics of the disease.
2) The PET-CT unit
Since June 2001, the Institut Jules Bordet has had a positron emission tomography (PET) centre. This centre was opened as part of a collaboration with other public hospitals in Brussels, within the IRIS hospital network. It is one of the 20 PET centres recognised by royal decree in Belgium. In 2016, this unit carried out 6000 PET-CT scans using different types of tracer.
3) Molecular radiotherapy
The Jules Bordet Institute is a reference centre for radionuclide therapy, historically with the treatment of thyroid cancer by iodine-131 and MIBG for neuroblastoma. Recent years have seen the development of several new treatments in the field of nuclear medicine, in particular for patients with neuroendocrine tumours (PRRT: protein receptor radio therapy) and prostate cancer metastasis and recurrence (PRLT: PSMA targeted radioligand therapy).
The treatments available at the Institut Jules Bordet:
- Lu177-octreotate (PRRT, for metastatic neuroendocrine tumours)
- Lu177-PSMA ligand (PRLT, for a multimetastatic recurrence of prostate cancer)
- Y90-microspheres (radioembolization of primary liver tumours or liver metastases)
- Xofigo (Radium-223) for bone metastases of prostate origin
- Iode-131 (thyroid cancer)
- MIBG (neuroblastoma)
- Y90-Zevalin (CD20-positive lymphoma)
The Department of Nuclear Medicine is the national reference unit where “Lymphology” is concerned. Indeed the nuclear medicine techniques make it easy to carry out a functional study of various pathologies of the lymphatic system. These techniques prove to be particularly useful in targeting certain oedemas (post-therapeutic “large arm” or “large leg” syndrome or primary or secondary lymphoedemas) and help in choosing the best treatment.
The Department of Nuclear Medicine is a training unit recognised for the training of doctors specialising in nuclear medicine (complete training programme).
Each year, it welcomes 1 or 2 young doctors training in nuclear medicine, as well as students on a masters in medicine course (1 or 2 per month). It organises regular seminars recognised to be part of in-service training of specialist doctors.
The Department also welcomes trainees training to be medical technologists.
The Department of Nuclear Medicine of the Institut Jules Bordet is the only service of the ULB network which provides systemic radionuclide cancer treatments (thyroid and neuroendocrine cancers). It has therefore become a national and international reference centre for specific training in “theranostics” and molecular radiotherapy.
Etude pilote d’imagerie PSMA-PET/CT en vue d’explorer la possibilité d’une thérapie basée sur le PSMA comme future option thérapeutique chez les patientes atteintes d’un cancer du sein métastatique triple négatif.
Head of Department
- Prof Patrick Flamen
- Dr Géraldine Gebhart, Head of Clinic
- Dr Carlos Artigas, Assistant Head of Clinic
- Dr Ioannis Karfis, Assistant Head of Clinic
- Dr Elçin Özalp, Assistant Head of Clinic
- Dr Erwin Woff, Assistant Head of Clinic
- Dr Ivan Duran Derijckere, Resident
- Marie Christiane Yimo-Wadje
- Théo Moschidis
- Prof. Zéna Wimana, Manager Radiopharmacy
- Prof. Ghanem Ghanem
- Adriana De Matos, Operator Radiopharmacy
- Kadidja Ouldadda, Operator Radiopharmacy
- Sigrid Vercauteren, Radiopharmacist
Coordination of radionuclide treatments
- Marie-Noëlle Gheeraert
- Pauwel Thijs
- Prof. Zéna Wimana, Radiopharmacy/pre-clinical imaging
- Wendy Delbart, PhD Student/Research Assistant/ Biomedical Sciences, ULB
- Loubna Taraji Schiltz, Clinical Study Coordinator
- Magdalena Mileva, MD, PhD Student/ Biomedical Sciences, ULB
- Qaid Shagera, MD, PhD Student/ Biomedical Sciences, ULB
- Ester Vicastillo Paredes, PhD Student/ Biomedical Sciences, ULB
- Gabriela Critchi, Research Assistant
Sara Coelho, Head of Technologists
Alyssa Hammouda (PET-Scan)
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Authors : Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, Macpherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM
Year : 2022
Journal : Eur J Cancer
Volume : 164
Pages : 39-51
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
Authors : Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, Gnesin S, Bodei L, Kracmerova T, Luster M, Garin E, Herrmann K
Year : 2022
Journal : Eur J Nucl Med Mol Imaging
The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma.
Authors : Rodríguez-Fraile M, Tamayo Alonso P, Rosales JJ, de Arcocha-Torres M, Caresia-Aróztegui AP, Cózar-Santiago MP, Orcajo-Rincon J, Simó Perdigó M, Delgado Bolton RC, Artigas C
Year : 2022
Journal : Rev Esp Med Nucl Imagen Mol (Engl Ed)
Volume : 41
Pages : 126-135
An Atypical Behavior of Metastatic Lung Disease in a Young Woman With Osteosarcoma: A Case Report.
Authors : Acquisto A, Duran Derijckere I, De Angelis R
Year : 2022
Journal : Cureus
Volume : 14
Pages : e21589